Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Monoclonal antibodies driving contract manufacturing’s growth in 2023.
October 1, 2024
By: Smita Khanna
The biopharmaceutical manufacturing segment has demonstrated remarkably consistent growth over the past 20+ years. Even during the current post-COVID economic environment where investment in biologics R&D has been reducing, the overall long-term outlook remains strong for global bioproduction. This has moved the production and even the innovation of these critical products beyond the borders of the current established markets in the U.S. and Europe. Since the start of the pandemic the use of contract development and manufacturing organizations (CDMOs) and the use of single use bioprocessing equipment (SUS) has grown. According to the 21st Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production published by BioPlan Associates,1 CDMO services during COVID increased dramatically, growing from $7 billion in 2018 to $18 billion in 2023. This is more than double the revenue pre-pandemic. However, the segment’s underlying growth, which had been running in the 9-12% range, would have doubled nearly every five years regardless. What pushed the revenue growth rate to approximately 10% in 2023 was the fact that CDMO services are simply in higher demand. Though growth had weakened a bit as compared to previous years, owing to the post COVID recovery, overall, the segment is growing steadily. Data from BioPlan’s 21st Annual Report1 also suggests 73.1% of biologics developers plan some level of outsourcing in 2024 for mammalian cell culture. This marks a decrease in in-house production to 26.9% from previous years, continuing a trend of increasing reliance on external manufacturing services to enhance flexibility and capability. Similarly, for microbial fermentation, 30.2% of respondents intend to keep all production in-house, showing a gradual decrease from previous years. For the advanced modalities like cell or gene therapies, outsourcing trends fluctuate more distinctly in this category, with only 30.4% of production remaining completely in-house. The spread of outsourcing percentages across various levels (from 1% to over 50%) reflects the specialized nature of these therapies and the strategic use of CDMOs to handle high-value, complex productions.1 On top of this fundamental growth, when COVID hit, the segment quickly responded to new market demands and was able to extend its capacity, scope of modalities, and manufacturing. For instance, in 2019, before COVID, few CDMOs were involved in the production of large amounts of mRNA. Now in 2024, only a few years later, a wide range of companies have adopted this novel molecule class and established new capabilities. The expansion towards new and more sophisticated modalities, mRNA, cell and gene therapies or antibody drug conjugates (ADCs) leads to the formation of specialized companies that lend themselves to become acquisition targets for established CDMOs needing to complement existing capabilities. Examples include the acquisitions of Seagen by Pfizer and Immunogen by AbbVie. Another significant acquisition in the CDMO industry is Novo Nordisk’s acquisition of Catalent. Consumables suppliers such as Thermo Fisher Scientific, Sartorius and others have successfully entered the CDMO market space by acquiring smaller contract manufacturers. These newly integrated CDMOs will benefit from early access to new technologies or reduced consumable costs and a more secure material supply chain. We have also seen examples of more established companies searching for partners to get their products outsourced to free up internal capacity for new, upcoming pipeline products.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !